TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who currently face lengthy treatment regimens. Read Here.
top of page
Recent Posts
See AllThis report marks the midway point of the 1/4/6×24 Campaign, which calls for the universal implementation of the best available TB regimens — as little as one month or once weekly for TB prevention, f
20
Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full
30
The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
380
bottom of page